NASDAQ: INSM · Biotechnology
Insmed (INSM) fair value and price range
As of 10 Oct 2026, Faircurve's model values Insmed (INSM) at $101.57 a share. The stock last closed at $96.79, which puts the model's fair value 4.9% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 13 Oct 2026. Insmed Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 10 Oct 2026 moved the fair value from $112.19 to $101.57 (-9.5%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $96.79 is 4.9% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextReports on 29 Oct 2026. Options expiring after the report price a move of about 16% either way. The next weekly run is on Saturday 17 Oct 2026.
What price range does the model give INSM?
The calibrated range for INSM over 63 trading days is $80.59 to $125.82. It sits around the last close, and its width comes from the volatility that INSM's own options imply (64% a year), calibrated weekly against realised prices (n = 4,266 past valuations, refreshed 10 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $65.03 to $152.53. In 51% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 10 Oct 2026
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company is in the Healthcare, Biotechnology sector.
Faircurve's model valued Insmed Incorporated at $101.57 a share on 10 Oct 2026, the midpoint of 2,000 simulations. The previous run on 3 Oct 2026 gave $112.19, a move of -9.5%. The model's fair value moved because the multiple the model anchors on moved, lowering the fair value, which was most of the move. The calibrated range over 63 trading days is $80.59 to $125.82, built around the price from the volatility the stock's own options imply, calibrated weekly against realised prices (4,266 past valuations, refreshed 10 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
The model compares Insmed Incorporated with Incyte Corporation (INCY), Roivant Sciences Ltd. (ROIV), Alnylam Pharmaceuticals, Inc. (ALNY), Exelixis, Inc. (EXEL), Neurocrine Biosciences, Inc. (NBIX), and Halozyme Therapeutics, Inc. (HALO). United Therapeutics Corporation (UTHR) and Jazz Pharmaceuticals plc (JAZZ) are also comparable companies but have no verdict on this date.
Written from the figures on this page for the 10 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does INSM report earnings, and how has the stock reacted?
Insmed's next earnings report is scheduled for 29 Oct 2026. Companies can move their dates.
Options prices on 13 Oct 2026 imply a move of about 16.2% in either direction through the nearest expiry, about 37 days out, a window that includes the report. That is the size the market is pricing, not a direction. INSM's 30 day implied volatility works out to about 18.4% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across INSM's last 8 reports, ignoring direction, was 6.7%.
Earlier reports are left out: the options record is on a different share basis.
What the options market has priced for a month's move in INSM
How does INSM compare with similar companies?
The companies in biotechnology closest to Insmed in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| INCY Incyte Corporation | $108.62 | $127.10 | +17.0% | Undervalued |
| UTHR United Therapeutics Corporation | $543.40 | $550.98 | +1.4% | Low evidence grade |
| ROIV Roivant Sciences Ltd. | $33.35 | $33.25 | -0.3% | Fairly valued |
| ALNY Alnylam Pharmaceuticals, Inc. | $223.82 | $267.97 | +19.7% | Undervalued |
| EXEL Exelixis, Inc. | $59.51 | $62.34 | +4.8% | Fairly valued |
| NBIX Neurocrine Biosciences, Inc. | $135.13 | $158.84 | +17.5% | Undervalued |
| JAZZ Jazz Pharmaceuticals plc | $210.39 | $259.50 | +23.3% | Low evidence grade |
| HALO Halozyme Therapeutics, Inc. | $109.62 | $108.46 | -1.1% | Fairly valued |
Insmed at a glance
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions.
- Market value
- $21.8B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $2.6B
- Consensus revenue growth, next fiscal year
- +196.3%
- Analysts with estimates
- 15
- Beta to the US market
- 0.49
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Insmed on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 3 Oct 2026 the model's fair value for INSM was $112.19. As of 10 Oct 2026 it is $101.57, a change of -9.5%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Insmed's valuation
Is Insmed stock undervalued or overvalued?
Faircurve's model puts INSM's fair value at $101.57 a share against a last close of $96.79, as of 10 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is INSM's fair value?
$101.57 a share as of 10 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $65.03 to $152.53.
What price range does the model give INSM?
$80.59 to $125.82 over 63 trading days. Ranges built this way held the price 60% of the time across 4,266 past valuations, refreshed 10 Oct 2026.
When does Insmed report earnings next?
The next report is scheduled for 29 Oct 2026. Companies can move their dates.
How much has INSM moved on past earnings reports?
Across its last 8 reports the median two session move was 6.7%, ignoring direction. The largest was +32.4% around the report of 6 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for INSM is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on INSM
The model holds no idea open on INSM today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on INSM with their outcomes. A free account is enough.